Cite
Verhelle A, Nair N, Everaert I, et al. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Hum Mol Genet. 2017;26(15):3030doi: 10.1093/hmg/ddx207.
Verhelle, A., Nair, N., Everaert, I., Van Overbeke, W., Supply, L., Zwaenepoel, O., Peleman, C., Van Dorpe, J., Lahoutte, T., Devoogdt, N., Derave, W., Chuah, M. K., VandenDriessche, T., & Gettemans, J. (2017). AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Human molecular genetics, 26(15), 3030. https://doi.org/10.1093/hmg/ddx207
Verhelle, Adriaan, et al. "AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model." Human molecular genetics vol. 26,15 (2017): 3030. doi: https://doi.org/10.1093/hmg/ddx207
Verhelle A, Nair N, Everaert I, Van Overbeke W, Supply L, Zwaenepoel O, Peleman C, Van Dorpe J, Lahoutte T, Devoogdt N, Derave W, Chuah MK, VandenDriessche T, Gettemans J. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Hum Mol Genet. 2017 Aug 01;26(15):3030. doi: 10.1093/hmg/ddx207. PMID: 28605435.
Copy
Download .nbib